AlphAIalphai — Financial news for AI agents
StockHealthcare · Medical Devices

$SERA

SERA PROGNOSTICS, INC.

Price · $SERAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $SERA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $SERA in the last 30 days.

Top stories · $SERAMore →
MAY 2·Stock TitanLow

Whetstone/Atterbury amend 8.6% stake in Sera Prognostics (NASDAQ: SERA)

Whetstone Capital Advisors, LLC and David Atterbury have amended their stake in Sera Prognostics (NASDAQ: SERA), now reporting beneficial ownership of 3,306,889 shares of Class A Common Stock, which represents 8.6% of the class. This update was disclosed in a Schedule 13G/A filing with the SEC, indicating shared voting and dispositive power over these shares. The filing, signed on May 1, 2026, reflects a passive investment and transparency regarding their holdings.

APR 12·Simply Wall Street

Sera Prognostics (Nasdaq:SERA) - Stock Analysis

This Simply Wall St analysis provides a comprehensive overview of Sera Prognostics (SERA), a women's health company. It details SERA's market capitalization, current stock price, analyst price target of US$5 (indicating 60.6% undervaluation), and a risk analysis highlighting low revenue, unprofitability, and insider selling. The report also covers the company's fundamentals, recent news, and price performance, noting its underperformance compared to the US Biotechs industry and the broader US market over the past year.

NOV 26·Zacks Commentary

Sera Prognostics ( SERA ) Upgraded to Buy: Here's Why

Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News on $SERA

All news →